According to the latest study from BCC Research, “Global Markets for Infectious Disease Treatments” is expected to grow from $72.5 billion in 2025 to $101 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.9% during the forecast period of 2025 to 2030.
This report analyzes the global market for infectious disease therapeutics, vaccines, and diagnostics, covering diseases such as HIV, influenza, hepatitis B and C, RSV, TB, HSV, malaria, rotavirus, and viral hemorrhagic fevers. It highlights market trends, challenges, and opportunities, along with insights into new products, acquisitions, collaborations, and ESG developments. The report also ranks leading companies by market share and provides detailed profiles of them. Excluded from the report are vector control strategies, symptomatic treatments, generic suppliers, and certain hospital-based diagnostic methods.
This report is particularly relevant today because the COVID-19 pandemic has reshaped global priorities around infectious diseases. It exposed critical gaps in healthcare systems and underscored the urgent need for rapid diagnostics, effective treatments, and scalable vaccine platforms. In response, governments, organizations, and private companies invested in infectious disease research and infrastructure, driving innovation and global collaboration. The pandemic also highlighted the importance of early detection, surveillance, and preparedness, leading to renewed attention on emerging and neglected infectious diseases.
Read Also: Otto Launches AI Recap, the First Scribe Tool that is Built for the Whole Picture of Veterinary Care
